Radiographic and Histologic Response to Neoadjuvant Radiotherapy in Patients With Soft Tissue Sarcoma by Canter, Robert J. et al.
ORIGINAL ARTICLE – BONE AND SOFT TISSUE SARCOMAS
Radiographic and Histologic Response to Neoadjuvant
Radiotherapy in Patients With Soft Tissue Sarcoma
Robert J. Canter, MD
1, Steve R. Martinez, MD, MAS
1, Robert M. Tamurian, MD
2, Maaya Wilton, MD
3,
Chin-Shang Li, PhD
4, Janice Ryu, MD
5, Walter Mak, MD
6, Wayne L. Monsky, MD, PhD
6,
and Dariusz Borys, MD
3
1Division of Surgical Oncology, University of California Davis Medical Center, Sacramento, CA;
2Division of Orthopedic
Oncology, University of California Davis Medical Center, Sacramento, CA;
3Department of Pathology and Laboratory
Medicine, University of California Davis Medical Center, Sacramento, CA;
4Division of Biostatistics, Department of
Public Health Sciences, University of California Davis, Sacramento, CA;
5Department of Radiation Oncology, University
of California Davis Medical Center, Sacramento, CA;
6Department of Radiology, University of California Davis Medical
Center, Sacramento, CA
ABSTRACT
Background. Limited data exist regarding the radio-
graphic and histologic response of soft tissue sarcoma
(STS) to neoadjuvant radiotherapy (RT).
Methods. Between February 2000 and January 2009, a
total of 25 patients aged [16 years with intermediate- or
high-grade primary STS of all sites were treated with
neoadjuvant RT followed by deﬁnitive resection. Patients
receiving chemoradiotherapy were excluded. Cross-sec-
tional images obtained before and after RT as well as
pathologic specimens were reviewed for maximal change
in tumor diameter and percentage tumor necrosis, respec-
tively. Clinicopathologic variables were analyzed for their
association with pathologic and radiographic response.
Results. There were 18 extremity (72%) and 7 retroperi-
toneal (28%) tumors. Median maximal tumor size was
9 cm (range, 3.3–35 cm), and 88% were of high grade.
There were 21 R0 resections (84%) and 4 R1 resections
(16%). Radiographically, the median percentage change in
tumor diameter was 0% (range, -25 to ?86%). By
Response Evaluation Criteria in Solid Tumors (RECIST), 5
patients demonstrated progressive disease, 20 demon-
strated stable disease, and 0 demonstrated partial/complete
response. The median pathologic percentage tumor necro-
sis was 30% (range, 5–100%). Two tumors (8%)
demonstrated near-complete pathologic response (C95%
necrosis). Near-complete pathologic response was associ-
ated with favorable oncologic outcomes, although these
associations were not statistically signiﬁcant.
Conclusions. Radiologic and near-complete pathologic
responses are rare events after preoperative RT for STS.
Near-complete pathologic response may be a potentially
meaningful surrogate marker for disease outcome and is
not predicted by RECIST response. Knowledge of these
historical response rates is important for the evaluation of
novel neoadjuvant therapies for patients with STS.
External-beam radiotherapy (RT) is an important com-
ponent of the multimodality treatment of patients with
localized soft tissue sarcoma (STS) and has contributed
substantially to both effective local disease control and
successful limb-sparing surgery.
1 Since the publication of
the landmark National Cancer Institute of Canada ran-
domized trial comparing preoperative to postoperative RT
for patients with extremity STS, preoperative RT for STS
has been widely accepted. Although oncologic outcomes
are essentially equivalent regardless of the timing of RT,
many clinicians favor preoperative RT because treatment
ﬁelds are well-deﬁned and long-term, potentially irrevers-
ible, RT-related complications are fewer.
2,3
Among patients with retroperitoneal sarcoma (RPS), data
examining the use of preoperative RT are predominantly
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trials have reported favorable results, neoadjuvant RT for
RPS remains controversial, and a recent randomized phase
III trial of preoperative external beam radiation with resec-
tioncomparedtoresectionalonesponsoredbytheAmerican
College of Surgeons Oncology Group was closed early
because of poor accrual.
Nevertheless, interest in preoperative RT for patients
with extremity and retroperitoneal STS remains wide-
spread, and ongoing studies are investigating the role of
preoperative RT for STS, particularly when administered in
combination with novel targeted agents (http://www.
clinicaltrials.gov/ct2/results?term=neoadjuvant?sarcoma).
Given the interest in investigational treatment approaches
combining preoperative RT with novel agents, we sought
to determine our historical response rates to neoadjuvant
RT monotherapy to provide a benchmark for comparison in
future studies. We also sought to determine whether the
surrogate end points of pathologic and radiologic response
to preoperative RT were associated with deﬁnitive onco-
logic outcome.
PATIENTS AND METHODS
From February 2000 and January 2009, a total of 45
patients with localized STS were treated with neoadjuvant
external beam RT followed by resection with curative
intent. These patients were prospectively entered and
tracked in a computerized cancer center database. Fourteen
patients with low-grade primary tumors and six patients
who received combination preoperative chemoradiotherapy
were excluded from this analysis. The remaining 25
patients formed the basis of this study.
Preoperative RT was administered in 2-Gy fractions over
25 sessions for a total dose of 50 Gy. Surgical resection was
performed approximately 4 to 6 weeks after the completion
of RT to allow for acute toxicities to resolve.
After approval for this study by the Institutional Review
Board, clinical, pathologic, and treatment data were
reviewed and analyzed with respect to percentage patho-
logic necrosis in the tumor specimen at the time of surgical
resection as well as Response Evaluation Criteria in Solid
Tumors (RECIST) response on pre- and post-RT cross-
sectional imaging. Local recurrence-free survival, distant
recurrence-free survival, disease-speciﬁc survival, and
overall survival were also calculated.
Hematoxylin and eosin–stained slides were reviewed in
a blinded fashion by a single STS pathologist (D.B.). The
percentage of histologically intact tumor and the percent-
age of necrotic tumor were scored per slide, and the mean
percentage of tumor necrosis was calculated for the entire
specimen, excluding nonneoplastic tissue. The median
number of stained slides examined per patient was 10
(range, 8–18).
Cross-sectional images obtained before and after RT
were reviewed by a single musculoskeletal radiologist
(W.M.) in a blinded fashion. Among extremity STS,
magnetic resonance imaging was used exclusively in all 18
cases. Among retroperitoneal STS, magnetic resonance
imaging was used in ﬁve of seven cases, computed tomo-
graphic scan in one of seven cases, and both modalities in
one of seven cases. Tumors were evaluated in three
dimensions, and maximal tumor diameter was ascertained.
Percentage change in maximal radiographic tumor dimen-
sion and RECIST response were calculated (http://ctep.
cancer.gov/protocolDevelopment/docs/recist_guideline.pdf).
Data were collected on age, sex, tumor location, histo-
logic type, primary tumor size, maximal tumor diameter,
histologic grade, tumor depth, margin status, extent of
resection, presence of myxoid histology, and disease
recurrence. Major wound complications were classiﬁed
according to standardized deﬁnitions.
Histologic grade was classiﬁed by a three-tiered system
(grade I through III). Age was determined from the date of
diagnosis of the primary tumor. Depth was categorized as
either superﬁcial or deep to the investing fascia. By conven-
tion, size of the primary tumor was divided into three groups:
B5c m ,[5c mb u tB10 cm, and [10 cm. Sites included
extremity(upperatordistaltotheshoulder/axilla,andlowerat
or distal to the buttock/groin) and retroperitoneal.
Histologic diagnosis was assigned by the published
criteria of the World Health Organization Classiﬁcation of
Tumors of Soft Tissue and Bone. Margin status was
determined either clinically (R2 for gross residual tumor
left behind) or as part of the histopathologic assessment
(R1 for microscopically positive margins, and R0 for
microscopically negative margins).
The date of recurrent disease was deﬁned either by
biopsy or by the radiographic detection of suspicious
lesions when no biopsy was performed. Peritoneal recur-
rences of intra-abdominal and RPS were considered local
recurrences, whereas liver metastases were considered
distant recurrences. Follow-up was counted from the date
of diagnosis until the date of death or date of last follow-
up. Freedom from local recurrence was counted from the
date of resection. Patients who were free from recurrence
or death were censored according to the date of their last
follow-up.
Summary statistics were reported as mean ± standard
deviation with median (range) where appropriate. Statisti-
cal analyses were performed by SAS version 9.1 (SAS
Institute, Cary, NC). Nonparametric numerical variables
were compared by the Mann–Whitney U-test for two
groups or the Kruskal–Wallis test for three groups. The
Kaplan–Meier approach was used to estimate survival
Response to Radiotherapy in Soft Tissue Sarcoma 2579curves, and survival differences were analyzed by the log
rank test.
8 Signiﬁcance was set at P\0.05.
RESULTS
Patient and Tumor Characteristics
The clinicopathologic characteristics of the patient
cohort are depicted in Table 1. The median age was
62 years (range, 22–86 years), and 56% were women. The
site of primary tumor was most commonly the lower
extremity (44%); there was an equal prevalence of upper
extremity (28%) and retroperitoneal (28%) tumors. The
median maximal tumor diameter was 9 cm (range, 3.3–
35 cm), 88% were of high grade, and 96% were located
deep to the investing fascia. Seven histologic subtypes
were present, including malignant ﬁbrous histiocytoma/
pleomorphic sarcoma (32%), leiomyosarcoma (24%), and
myxoid/round cell liposarcoma (20%).
Among 18 patients with extremity tumors, 17 (94%)
were managed successfully with limb-sparing surgery
(Table 2). One patient underwent a hip disarticulation for a
24-cm proximal thigh pleomorphic sarcoma involving the
posterior and medial compartments from the inferior pubic
ramus to the popliteal fossa. An R0 resection was achieved
in 84% of patients, and there were no R2 resections. Major
wound complications (as deﬁned by O’Sullivan et al.)
occurred in seven patients (28%). These were more com-
mon with lower extremity tumors.
2
TABLE 1 Clinicopathologic characteristics of 25 soft tissue sar-
coma patients undergoing preoperative radiotherapy and surgical
resection with curative intent
Characteristic Value
Sex, n (%)
Male 11 (44)
Female 14 (56)
Age at diagnosis (y), median (range) 62 (22–86)
Site, n (%)
Lower extremity 11 (44)
Upper extremity 7 (28)
Retroperitoneal 7 (28)
Histology, n (%)
Malignant ﬁbrous histiocytoma/pleomorphic 8 (32)
Leiomyosarcoma 6 (24)
Myxoid/round cell liposarcoma 5 (20)
Synovial 3 (12)
Other
a 3 (12)
Primary tumor size, n (%)
B5 cm 2 (8)
5–10 cm 14 (56)
[10 cm 9 (36)
Maximal tumor diameter (cm), median (range) 9 (3.3–35)
Grade, n (%)
Intermediate 3 (12)
High 22 (88)
Depth, n (%)
Deep 24 (96)
Superﬁcial 1 (4)
Margin status, n (%)
R0 21 (84)
R1 4 (16)
a Includes one mesenchymal chondrosarcoma (4%), one extraskeletal
osteosarcoma (4%), and one sarcoma, not otherwise speciﬁed (4%)
TABLE 2 Treatment and response among 25 soft tissue sarcoma
patients undergoing preoperative radiotherapy and surgical resection
with curative intent
Characteristic Value
Extent of resection, n (%)
Limb-sparing surgery 17 (68)
Amputation 1 (4)
Laparotomy 7 (28)
Major wound complications,
a n (%)
Yes
b 7 (28)
No 18 (72)
Percentage change maximal tumor diameter,
median (range)
0( -25 to ?86)
RECIST response, n (%)
Complete response/partial response 0 (0)
Stable disease 20 (80)
Progressive disease 5 (20)
Percentage pathologic tumor necrosis, median
(range)
30 (5–100)
Disease recurrence, n (%)
Local 0 (0)
Distant 7 (28)
None 18 (72)
Status at last follow-up, n (%)
No evidence of disease 17 (68)
Alive with disease 3 (12)
Dead of other causes 2 (8)
Dead of disease 3 (12)
RECIST, Response Evaluation Criteria in Solid Tumors (http://
ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf)
a As deﬁned by O’Sullivan et al
2
b Includes four patients (16%) requiring secondary operation for
wound repair, two patients (8%) requiring readmission for wound
care, and one patient (4%) requiring an invasive procedure for wound
management
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With a median follow-up of 19 months (range, 4–113),
3-year overall survival, local recurrence-free survival, and
distant recurrence-free survival were 80, 100, and 59%,
respectively (Fig. 1). Disease-speciﬁc survival was 88%
(data not shown). As depicted in Table 2, seven patients
developed distant metastases, 3 of whom died of disease.
One patient was rendered free of disease after pulmonary
metastasectomy, and three patients received systemic
chemotherapy for metastatic disease.
Radiographic and Pathologic Response
and Association with Outcome
As depicted in Table 2, the median percentage change in
maximal tumor diameter on serial cross-sectional images
before and after RT (before resection) was 0% (range, -25
to ?86%). This corresponded to 0 complete/partial
responses by RECIST, 20 stable disease (80%), and 5
progressive disease (20%). The distribution of these
radiographic responses is shown in Fig. 2a.
The median percentage pathologic necrosis on histo-
logic examination of the resected specimens was 30%
(range, 5–100%). Two tumors (8%) demonstrated complete
or near-complete pathologic response (C95% necrosis)
after preoperative RT. The distribution of tumor necrosis
per patient is depicted graphically in Fig. 2b.
As depicted in Fig. 3, complete or near-complete path-
ologic response was associated with favorable distant
recurrence-free survival (100% 3-year event-free survival
vs. 59% 3-year event-free survival). This association,
however, was not statistically signiﬁcant (P = 0.50).
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FIG. 1 Kaplan–Meier curve depicting local recurrence-free survival,
overall survival, and distant recurrence-free survival for the entire
cohort of soft tissue sarcoma patients treated with preoperative
radiotherapy followed by resection with curative intent
40
20
0
-20
80
60
100
a
Radiographic % Change
Maximal Tumor Diameter
Individual Cases
(N = 25)
40
20
80
60
100
b
% Tumor Necrosis
Individual Cases
(N = 25)
FIG. 2 a Waterfall plot of
radiographic percentage change
in maximal tumor diameter
(RECIST response) from initial
diagnosis to restaging after
preoperative radiotherapy.
RECIST, Response Evaluation
Criteria in Solid Tumors
(http://ctep.cancer.gov/
protocolDevelopment/docs/
recist_guideline.pdf). (b) Water-
fall plot of percentage tumor
necrosis in resected surgical
specimens after preoperative
radiotherapy for soft tissue
sarcoma
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FIG. 3 Kaplan–Meier curve depicting distant recurrence-free sur-
vival grouped by presence or absence of near-complete pathologic
necrosis in resected surgical specimen (C95% tumor necrosis). Log
rank test P value is shown
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As depicted in Fig. 4, tumors with myxoid histology
demonstrated signiﬁcantly more tumor necrosis after pre-
operative RT than tumors without myxoid histology (mean
percentage necrosis 69 ± 27% for myxoid histology vs.
29 ± 28% for nonmyxoid histology, P = 0.003). In con-
trast, none of the following demonstrated statistically
signiﬁcant differences in percentage tumor necrosis after
preoperative RT: grade (intermediate grade mean per-
centage necrosis 50 ± 20% vs. high 39 ± 33%, P =
0.34); location (retroperitoneal mean percentage necrosis
24 ± 13% vs. upper extremity 38 ± 32% vs. lower
extremity 52 ± 39%, P = 0.50); size (\5 cm mean per-
centage necrosis 10 ± 4% vs. 5–10 cm 44 ± 29% vs.
[10 cm 42% ± 40%, P = 0.33); and RECIST response
(stable disease mean percentage necrosis 41 ± 33% vs.
progressive disease 37 ± 33%, P = 0.88).
DISCUSSION
RT is an important component of local therapy among
patients with STS of the extremity and body wall.
1 It has
been shown to reduce local recurrence rates by 20% to 25%
relative to radical resection alone.
9 For patients with RPS,
interest in preoperative RT remains widespread because the
risk of local treatment failure is substantial and because
local failure frequently contributes to patient death.
10
Despite the frequent administration of preoperative RT
for extremity and retroperitoneal STS, there are limited
data examining the impact of RT as monotherapy on short-
term end points such as radiographic tumor size or patho-
logic necrosis in the surgical specimen. For example, no
study of preoperative RT to date has reported radiographic
and pathologic response rates after treatment among
patients with RPS. Among patients with extremity STS,
Willett et al. reported C80% tumor necrosis in 78% of
preoperatively irradiated patients.
11 The prevalence of
greater degrees of pathologic necrosis in this study may
have been the result of twice-daily (total dose 4770 cGy)
fractionation in a substantial percentage of patients.
Although these patients did experience higher overall
amounts of tumor necrosis, there was no correlation
between tumor necrosis and distant recurrence-free sur-
vival at the 80% threshold.
11 Hew et al. observed C80%
tumor necrosis among 35% of patients treated with a once-
daily regimen of preoperative RT, a rate which was
roughly comparable to that of the present study (25% of
tumors demonstrated C80% tumor necrosis).
12 Similar to
Willett et al., Hew et al. did not observe an association
between C80% pathologic tumor necrosis and distant
recurrence-free survival, suggesting that this threshold may
not be a biologically signiﬁcant surrogate end point.
12
A recent series from de Vreeze et al. demonstrated a
26% rate of complete pathologic response (100% necrosis)
after preoperative RT.
13 Although this rate of tumor
necrosis is greater than the current study, de Vreeze et al.
had a higher proportion of patients with myxoid liposar-
coma in their series, and the authors observed complete
pathologic response among this entire subgroup of patients.
Our ﬁndings do conﬁrm the ﬁndings of de Vreeze et al. as
well as those of other investigators that myxoid histology is
consistently associated with favorable tumor necrosis after
preoperative RT.
14,15 Conversely, data regarding the asso-
ciation of tumor size and histologic grade with pathologic
response are mixed, and our data indicate a lack of statis-
tically signiﬁcant association between these other
clinicopathologic factors and tumor necrosis.
11,12
Increasing data suggest that RECIST response is rare
after neoadjuvant therapy for STS.
16–19 Furthermore,
changes in radiographic tumor size, as measured by RE-
CIST, also seem to be a poor surrogate of disease control
and oncologic outcome.
18,20 Our ﬁndings are consistent
with both of these conclusions and reafﬁrm that novel
imaging end points for STS are needed.
17,21
Although the duration of follow-up was relatively short in
this series, preoperative RT followed by wide resection
demonstrated excellent local control (100% local recurrence-
free survival), even among patients with radiographically
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FIG. 4 Bar graph comparing mean percentage tumor necrosis strat-
iﬁed by various clinicopathologic characteristics. ** P = 0.003 by
Mann–Whitney U-test. RECIST Response Evaluation Criteria in Solid
Tumors; SD stable disease; PD progressive disease. Myxoid histology
includes 5 myxoid/round liposarcoma and 2 myxoﬁbrosarcoma
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complete pathologic response was associated with favor-
able oncologic outcome, the rarity of this event (8% of the
cohort) rendered our study underpowered to detect differ-
ences in survival outcomes, and the survival rates of
patients with near-complete pathologic response were not
statistically different from those of the entire cohort.
Although treatment-induced near-complete pathologic
necrosis has been shown to correlate with STS outcome
among patients treated with combination preoperative
chemoradiation, this association has not been examined in
studies of preoperative RT as monotherapy.
22,23 Because
RT is a local treatment modality, it is conceivable that
tumor necrosis after RT monotherapy is not associated with
oncologic outcomes (such as overall survival) that are
governed by the development of distant disease. However,
given the substantial toxicity of combination chemotherapy
regimens for STS, there is widespread interest in novel
investigational treatments for STS, particularly in combi-
nation with preoperative RT (http://www.clinicaltrials.gov/
ct2/results?term=neoadjuvant?sarcoma). This interest in
novel neoadjuvant STS therapies highlights the need for
additional studies to validate or refute near-complete
pathologic response as a potentially important surrogate
end point.
In summary, our data demonstrate that radiologic and
near-complete pathologic responses are rare events after
preoperative RT for STS. Near-complete pathologic
response may be a potentially meaningful surrogate marker
for disease outcome and is not predicted by RECIST
response. Surrogate markers of disease response and
prognosis are needed while waiting for longer oncologic
follow-up, and knowledge of these historical response rates
is important for the evaluation of novel neoadjuvant ther-
apies for patients with STS.
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